Roche's Actemra shows promise for sJIA in Phase III study
This article was originally published in Scrip
Executive Summary
Roche's first-in-class interleukin-6 inhibitor RoActemra (tocilizumab; known as Actemra outside of the EU) improved the signs and symptoms of systemic juvenile idiopathic arthritis (sJIA), full data from the Phase III TENDER study show. There are no approved treatments for sJIA in the US and the EU, but RoActemra was approved for the condition in Japan in 2008.